[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transient-ischemic-attack\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transient-ischemic-attack":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,45,73,98,132,156,191,214,236,266,296,320,347,373,399,430,457,479,510,545,576],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100642062","phase-4-platelet-aggregation-function-guided-de-escalation-antiplatelet-therapy-in-patients-with-acute-ischemic-stroke-100642062",false,"NCT07644234","Platelet Aggregation Function-Guided De-Escalation Antiplatelet Therapy in Patients With Acute Ischemic Stroke","PATH STROKE D","Inclusion Criteria:\n\n* 1.Age 18 years or older. 2.Diagnosis of acute non-disabling ischemic stroke or transient ischemic attack according to World Health Organization criteria, meeting one of the following definitions: acute non-disabling ischemic stroke, defined as a National Institutes of Health Stroke Scale score of 5 or lower at enrollment; or high-risk transient ischemic attack, defined as an ABCD2 score of 4 or higher.\n\n  3.Symptom onset within 48 hours. Onset time is defined as the interval from the last time the participant was known to be well to the time of combined administration of clopidogrel 300 mg and aspirin 100 mg.\n\n  4.MARADP \\\u003C35% measured 5 to 20 hours after combined antiplatelet treatment with clopidogrel 300 mg and aspirin 100 mg within 48 hours of symptom onset.\n\n  5.Planned treatment with aspirin plus clopidogrel or clopidogrel monotherapy for antiplatelet therapy.\n\n  6.Written informed consent provided by the participant or a legally authorized representative.\n\nExclusion Criteria:1.Imaging evidence of hemorrhagic stroke, hemorrhagic transformation, or another pathological brain disorder, such as vascular malformation, tumor, abscess, or another common non-ischemic brain disease such as multiple sclerosis.\n\n2.Minor stroke or transient ischemic attack caused by angioplasty or vascular surgery.\n\n3.Atrial fibrillation indicated by standard electrocardiography or typical physical signs of atrial fibrillation, including absolutely irregular rhythm, variable intensity of the first heart sound, or pulse deficit.\n\n4.A clear indication for anticoagulation, including suspected cardioembolism such as atrial fibrillation, known artificial heart valve, or suspected endocarditis.\n\n5.Intravenous thrombolysis, intra-arterial thrombolysis, mechanical thrombectomy, or any revascularization procedure performed after the index event or planned within 90 days.\n\n6.Use of antiplatelet agents other than aspirin or clopidogrel within 7 days before enrollment, such as ticagrelor or prasugrel.\n\n7.History of gastrointestinal bleeding, intracranial hemorrhage, recent major bleeding or blood transfusion, excluding minor hemoptysis or minor abnormal vaginal bleeding, or other bleeding disorder caused by coagulation dysfunction, such as purpura.\n\n8.Contraindication or intolerance to clopidogrel or aspirin, including known allergy; severe hepatic insufficiency or renal insufficiency; severe heart failure; coagulation disorder or history of systemic bleeding; history of thrombocytopenia or neutropenia; or history of drug-induced hematologic disease or hepatic dysfunction.\n\n9.Leukopenia, defined as white blood cell count \\\u003C2 x 10\\^9\u002FL, or thrombocytopenia, defined as platelet count \\\u003C100 x 10\\^9\u002FL.\n\n10.Use of heparin or oral anticoagulants within 10 days before enrollment. 11.Severe cardiac, pulmonary, hepatic, or renal dysfunction, or severe comorbid disease such as tumor, chronic airflow disease, severe dementia, or severe heart failure.\n\n12.Female participants of childbearing potential with a negative pregnancy test who refuse to use effective contraception, or women who are pregnant or breastfeeding.\n\n13.Poor compliance or inability to complete study requirements.\n\n\\-","ALL","18 Years",{"count":19,"type":20},3836,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","This multicenter, prospective, open-label, randomized controlled trial will evaluate whether platelet aggregation function-guided de-escalation of antiplatelet therapy is non-inferior in efficacy and superior in safety compared with standard dual antiplatelet therapy in patients with acute minor ischemic stroke or high-risk transient ischemic attack who are sensitive to clopidogrel.\n\nParticipants who present within 48 hours of symptom onset and meet the eligibility criteria will receive loading doses of clopidogrel and aspirin, followed by platelet aggregation function testing. Eligible clopidogrel-sensitive participants will be randomized to receive either 7 days of dual antiplatelet therapy followed by clopidogrel monotherapy or standard 21-day dual antiplatelet therapy followed by single antiplatelet therapy. The primary efficacy outcome is new stroke within 90 days after randomization.",[26,27],"Ischemic Stroke","Transient Ischemic Attack",[29,26,30,31],"Antiplatelet de-escalation","Platelet function tests","RCT","NOT_YET_RECRUITING","2026-06-08",{"date":35,"type":36},"2026-06-12","ACTUAL",{"date":38,"type":20},"2026-06",{"date":40,"type":20},"2029-10",{"name":42,"class":43},"Sichuan Provincial People's Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":44},"100642571","smartwatch-guided-secondary-prevention-after-stroke-100642571","NCT07640360","Smartwatch-Guided Secondary Prevention After Stroke","WATCH-STEP : Pilot Trial: Smartwatch-Guided Secondary Prevention After Stroke Randomized Trial of Nurse-led Program With Active vs Passive Smartwatch in Minor Stroke. A Randomized Controlled Trial Evaluating a Nurse-led Secondary Prevention and Physical Activity Program Supported by Either an Active Smartwatch (Structured Feedback) or Passive Smartwatch in Patients With Minor Stroke.","WATCH-STEP","Inclusion Criteria:\n\n* Age ≤ 40-75\n* Patients with recent minor ischemic stroke or TIA, initial NIHSS ≤5 (\\\u003C 30 days)\n* mRS ≤2 before stroke and on discharge\n* Patient with Wifi access (for data transmission)\n* Able to understand smartwatch instructions\n* Written informed consent\n* Ambulatory ≥10 meters without assistance and without walking aid\n* Expected to live at home during the study period.\n\nExclusion Criteria:\n\n* Patients with transient neurological deficits resolving within one hour and normal brain imaging will be excluded\n* Not affiliated to social security\n* Patient under legal protection or deprived of liberty by a judicial or administrative decision\n* Patient whose follow-up will be impossible\n* Cognitive impairment interfering with participation (e.g., MoCA \\\u003C20).\n* Unstable cardiac conditions preventing walking goals.\n* Major visual or upper limb impairment preventing use of the smartwatch.\n* Life expectancy \\\u003C1 year.\n* Already highly active (\\>10,000 steps\u002Fday, or about 1.5 hours of walking).\n* Participation in competing interventional trials.","40 Years","75 Years",{"count":56,"type":20},50,[58],"NA","After a first stroke or transient ischemic attack (TIA), the risk of recurrence is high in the weeks and months following the initial event. There are several modifiable risk factors that can reduce this risk, such as blood pressure, diet, physical activity, and smoking. Many stroke patients (NIHSS \\\u003C 5) have a low daily step count during the early recovery period, despite a good functional prognosis.\n\nActive smartwatches provide real-time feedback, track progress, and set personalized walking goals, thereby boosting motivation and adherence to physical activity recommendations.\n\nThe combination of advice provided by nurses and active behavioral coaching supported by a smartwatch, compared to passive monitoring, could significantly increase daily step counts over a 12-week period. The results of this research will help guide future large-scale secondary prevention strategies integrating digital health and structured nursing support.",[61,27],"Stroke",[63],"SMARTWATCH","2026-06-05",{"date":66,"type":36},"2026-06-10",{"date":68,"type":20},"2026-09",{"date":70,"type":20},"2027-12",{"name":72,"class":43},"University Hospital, Brest",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":44},"100640279","a-cluster-randomized-trial-of-a-telemedicine-enabled-integrated-care-model-for-stroke-prevention-and-management-in-rural-elderly-adults-in-china-100640279","NCT07628283","A Cluster Randomized Trial of a Telemedicine-Enabled Integrated Care Model for Stroke Prevention and Management in Rural Elderly Adults in China","A Prospective, Open-Label, Cluster Randomized Controlled Trial to Evaluate the Efficacy of a Rural Doctor-Led, Telemedicine-Supported Integrated Care Model for Reducing Cardiovascular and Cerebrovascular Events in Elderly Adults at High Risk of Stroke in China","Inclusion Criteria:\n\n1. Aged 65 years or older\n2. Rural residents with household registration or long-term residence (≥6 months\u002Fyear) in the study area\n3. High risk of stroke as defined by the National Health Commission's \"8+2\" stroke risk screening tool: ≥3 risk factors OR history of stroke\u002FTIA\n4. Willing to receive long-term health management from the assigned village clinic\n5. Written informed consent provided by the participant or their legal representative\n\nExclusion Criteria:\n\n1. Severe dementia or psychiatric disorder that prevents completion of study follow-up and assessments\n2. Life expectancy less than 1 year (e.g., advanced malignancy, end-stage renal disease)\n3. Currently participating in another interventional clinical trial","65 Years",{"count":82,"type":20},2510,[58],"This cluster randomized controlled trial aims to evaluate the effectiveness of a novel telemedicine-enabled integrated care model led by rural doctors in reducing cardiovascular and cerebrovascular events among elderly adults (≥65 years) at high risk of stroke in rural China. A total of 39 village clinics will be randomized to either the intervention group (digital health platform-supported integrated care) or the control group (enhanced usual care). The primary outcome is a composite of cardiovascular death, stroke, and hospitalization for heart failure or acute coronary syndrome at 36 months.",[61,86,87,27,88,89],"Brain Ischemia","Cerebral Hemorrhage","Cardiovascular Diseases","Hypertension","2026-05-28",{"date":64,"type":36},{"date":93,"type":20},"2026-06-01",{"date":95,"type":20},"2030-06-30",{"name":97,"class":43},"Jiangsu Province (Suqian) Hospital",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":109,"conditions":110,"keywords":114,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":44},"100535528","radiofrequency-and-cryoablation-of-the-posterior-wall-of-the-left-atrium-100535528","NCT06253000","Radiofrequency and Cryoablation of the Posterior Wall of the Left Atrium","Comparative Analysis of Radiofrequency and Cryoablation of the Posterior Wall of the Left Atrium in Patients With Persistent Atrial Fibrillation","Inclusion Criteria:\n\n* Age over 18 years old;\n* Atrial fibrillation resistant to antiarrhythmic therapy;\n* Persistent and long-persisting form of atrial fibrillation;\n* The patient's consent to participate in the study.\n\nExclusion Criteria:\n\n* Age under 18 and over 80 years old;\n* The presence of another cardiac pathology requiring surgical treatment;\n* Congenital heart defects;\n* Previous \"open\" cardiac surgery;\n* Bone marrow diseases;\n* Pathology of the blood coagulation system;\n* The left ventricular ejection fraction is less than 40%;\n* Moderate to severe renal insufficiency (creatinine clearance \\\u003C50 ml\u002Fmin);\n* Drug-resistant hypertension (despite hypotensive therapy);\n* Organically altered mitral valve;\n* There are reasons to assume that the patient will not show up for subsequent visits (control points of the study) for various reasons;\n* The patient's participation in another clinical trial.","80 Years",{"count":107,"type":20},158,[58],"Atrial fibrillation (AF) is the cause of 20% of strokes, and the risk of stroke in a person suffering from this arrhythmia increases by 5 times. Ischemic stroke in patients with AF is often fatal and, compared with stroke of other etiology, leads to the most pronounced disability and more often recurs. Accordingly, the risk of death in patients with AF-related stroke is 2 times higher, and treatment costs increase 1.5 times.\n\nThe main interventional method of treating AF, available in most medical institutions, is the use of radio frequency and\u002For cryoenergy to eliminate destructive damage to the left atrium (LA).\n\nThe aim of this study is to compare two different interventional methods and identify predictors of recurrence in patients with persistent and long-term AF.",[61,111,27,112,113],"Acute Cerebrovascular Accident","Death","Atrial Fibrillation Recurrent",[115,116,117,118,119,120],"atrial fibrillation","radiofrequency ablation","cryoablation","left atrium","the posterior wall of the left atrium","atrial remodeling","RECRUITING","2026-05-07",{"date":124,"type":36},"2026-05-08",{"date":126,"type":36},"2023-06-10",{"date":128,"type":20},"2026-12-30",{"name":130,"class":131},"Bakulev Scientific Center of Cardiovascular Surgery","OTHER_GOV",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":140,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":44},"100523107","florbetaben-for-imaging-of-vascular-amyloid-100523107","NCT06091319","Florbetaben for Imaging of Vascular Amyloid","Florbetaben for Imaging of Vascular Amyloid: Evaluation of Amyloid Inflammasome Imaging in Carotid and Coronary Arteries in Patients With Unstable Atherosclerosis- A Pilot Study","FERMATA","Inclusion Criteria:\n\n1. suffered a recent cardiovascular event (30-120 days post ACS (i.e. STEMI or NSTEMI) or TIA\u002Fstroke with ipsilateral large vessel atherosclerotic disease confirmed on US, CT or MRI;\n2. stable symptoms and hemodynamics;\n3. age \\>\u002F= 18 years;\n4. given informed consent.\n\nExclusion Criteria:\n\n1. a recent CV event likely to have been embolic in the opinion of the neurologist or cardiologist;\n2. severe LV dysfunction (EF\\\u003C30%);\n3. severe valve disease requiring intervention;\n4. decompensated heart failure;\n5. pregnancy (all women of child bearing potential will have a negative BHCG test;\n6. breastfeeding;\n7. women of childbearing potential who refuse to use two forms of contraception (this includes at least one form of highly effective and one effective method of contraception) throughout the study OR men capable of fathering a child who refuse to use contraception;.\n8. unable to give informed consent;.\n9. Florbetaben allergy;\n10. glomerular filtration rate (GFR) \\\u003C50 ml\u002Fmin\u002F1.72m2\n\nExclusion for CTA portion of the protocol: Patients with dye allergy, or those with GFR \\\u003C60, will not undergo CTA but will have PET\u002FCT.",true,{"count":142,"type":20},30,"OBSERVATIONAL","The Primary Objective is to determine if a new nuclear tracer (named 18F-Florbetaben) used with nuclear imaging (PET imaging) can detect inflamed plaque in patients with recent ACS or stroke\u002FTIA.",[146,61,27,147],"Acute Coronary Syndrome","Atherosclerosis of Artery","2026-05-05",{"date":124,"type":36},{"date":151,"type":36},"2023-10-09",{"date":153,"type":20},"2026-08-01",{"name":155,"class":43},"Ottawa Heart Institute Research Corporation",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":165,"conditions":166,"keywords":168,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":44},"100573028","imaging-and-serological-biomarkers-of-autonomic-dysfunction-after-ischemic-stroke-100573028","NCT06740942","Imaging and Serological Biomarkers of Autonomic Dysfunction After Ischemic Stroke","ARIADNE","Inclusion Criteria:\n\n* Diagnosis of either\n\n  * acute ischemic stroke with either an ischemic lesion visible on CT\u002FMRI or persistent focal deficits 24 hours after symptom onset, or\n  * Transient ischemic attack with transient clinical deficits including motor or speech disturbance and not restricted to isolated vertigo\u002Fdizziness, visual disturbance, or sensory disturbance.\n* symptom onset within 72h prior to hospital admission,\n* a pre-stroke\u002FTIA ability to walk without help from another person (modified Rankin scale score \\\u003C 4),\n* age \\> 18 years, and\n* informed consent by either the patient or a legal representative (including a spouse)\n\nExclusion Criteria:\n\n* In-hospital stroke,\n* contraindications to MR imaging (e.g., claustrophobia, pregnancy, pacemakers, implants),\n* known moderate to severe dementia,\n* previous structural brain damage (except leukoariosis due to cerebral small vessel disease),\n* hemodynamically relevant stenosis of the common or internal carotid artery, or\n* left heart failure with estimated left ventricular ejection fraction \\\u003C 50%,\n* concomitant systemic illness that can lead to dysautonomia, such as an active infection, thyroid disease, or neurodegenerative disorder (e.g. PD, MSA).",{"count":164,"type":20},100,"The goal of this observational study is to\n\n* to investigate the prevalence and time course of autonomic dysfunction in acute ischemic stroke patients;\n* to evaluate the influence of lesion location on autonomic dysfunction;\n* to identify patterns of structural and functional brain connectivity within the central autonomic control circuits associated with autonomic dysfunction; and\n* to explore causal models of the link between brain lesions; cardiac, immunological and endocrine biomarkers; and dysautonomia.\n\nResearchers will compare patients with acute ischemic stroke to patients with transient ischemic attacks to study the effect of acute ischemic brain lesions.\n\nParticipants will\n\n* undergo cardiovascular autonomic function testing;\n* receive structural and functional MR imaging;\n* provide blood samples for determinaton of serological biomarkers auf dysautonomia.",[167,27],"Acute Ischemic Stroke",[169,170,171,172,173,174,175,176,177,178,179,180,181,182],"Autonomic dysfunction","cardiovascular dysregulation","brain-heart axis","stroke-heart syndrome","acute ischemic stroke","transient ischemic attack","autonomic function test","central autonomic network","network lesion mapping","lesion symptom mapping","resting-state fMRI","functional brain network","structural brain network","diffusion tensor imaging","2026-05-01",{"date":122,"type":36},{"date":186,"type":36},"2025-08-04",{"date":188,"type":20},"2026-12",{"name":190,"class":43},"Universitätsklinikum Hamburg-Eppendorf",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":105,"enrollmentInfo":199,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":201,"conditions":202,"keywords":203,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":44},"100611606","follow-up-extension-study-of-regular-physical-exercise-in-patients-with-symptomatic-intracranial-arterial-stenosis-100611606","NCT07242768","Follow-up Extension Study of Regular Physical Exercise in Patients With Symptomatic Intracranial Arterial Stenosis","Regular Physical Exercise in Patients With Symptomatic Intracranial Arterial Stenosis: Three-year Follow-up of RESIST Trial","RESIST-FE","Inclusion Criteria:\n\n1. Participants who enrolled in the RESIST trial and completed the 12-month follow-up.\n2. Written informed consent to participate in this 3-year observational extension.\n\nExclusion Criteria:\n\nParticipants who withdrew consent in the RESIST trial, decline to participate in this extension, or were lost to follow-up at 12 months.",{"count":200,"type":20},1300,"This study will include the subjects with symptomatic intracranial arterial stenosis (ICAS) who have participated in and completed the 1-year follow-up of RESIST trial (NCT06615726). The aim is to observe the long-term clinical outcomes over 3 years after a 1-year regular physical exercise intervention in patients with symptomatic ICAS.",[26,27],[26,27,204],"Symptomatic intracranial arterial stenosis","2026-01-26",{"date":207,"type":36},"2026-01-27",{"date":209,"type":36},"2026-01-10",{"date":211,"type":20},"2028-11-30",{"name":213,"class":43},"Capital Medical University",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":223,"conditions":224,"keywords":226,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":44},"100619066","diagnosis-of-transient-ischemic-attacks-in-the-emergency-department-100619066","NCT07339787","Diagnosis of Transient Ischemic Attacks in the Emergency Department","DAITSU","Inclusion Criteria:\n\n* Adult (≥18 years old)\n* Having consulted the emergency department or been diagnosed with TIA during the period from January 1, 2024, to December 12, 2024 (records will be compiled via coding at the East Rescue regional emergency observatory)\n* TIA will be defined as a sudden, transient neurological deficit that had disappeared by the time of arrival at the emergency department\n\nExclusion Criteria:\n\n\\- Subjects with a suspected diagnosis of TIA, i.e., with a sudden, transient neurological deficit that had disappeared by the time of arrival at the emergency department.",{"count":222,"type":20},300,"Patients presenting a Transient Ischemic Attack (TIA) and admitted to the Emergency Department should be referred to a neurovascular specialist. In recent years, several hospitals have established TIA clinics. These units are day hospitals where all the necessary examinations are performed. Access to this expertise has proven beneficial in reducing cardiovascular morbidity and mortality, particularly the risk of early recurrence. Unfortunately, this access is limited by issues of medical demographics and unequal access to the healthcare system. In practice, this ideal care is not always possible. A portion of the TIA population is at low risk, and diagnostic and therapeutic interventions are limited, not always requiring neurovascular expertise.\n\nThe hypothesis of this research is that the management of a patient who has suffered a TIA (additional examinations, treatment, referral) is not linked to their cardiovascular risk and that the performance of additional examinations and therapies is incomplete.",[27,225],"Cardiovascular Morbidity",[27,225],"2026-01-05",{"date":229,"type":36},"2026-01-14",{"date":231,"type":36},"2025-02-06",{"date":233,"type":20},"2027-01-06",{"name":235,"class":43},"University Hospital, Strasbourg, France",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":21,"phases":244,"briefSummary":245,"conditions":246,"keywords":249,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":265},"100435051","stroke-school--including-physical-exercise-patient-education-and-individual-follow-up-sessions-100435051","NCT04945174","Stroke School -Including Physical Exercise, Patient Education and Individual Follow-up Sessions","Stroke School - Cross-sectorial Physical Exercise for Patients With Minor Stroke or Non-disabling Stroke","Inclusion Criteria:\n\n* Patients with a minor stroke or TIA without the need of rehabilitation after hospital discharge, but need physical activity in order to prevent cardiovascular diseases\n* Patients spending ≤ 5 hour of leisure time on high-intensity physical activity on weekly basis within the last 3 months\n* Able to speak and read Danish and to provide informed consent\n* Individuals ≥ 18 years of age\n\nExclusion Criteria:\n\n* Previous large-artery stroke or hemorrhagic stroke\n* Unstable cardiac condition, e.g. pacemaker\n* Uncontrolled hypertension (patients not responding adequately to antihypertensive medication when applying treatment according to guidelines)\n* Symptoms or comorbidities not allowing exercise on a stationary bicycle (e.g. claudication)\n* Dyspnoea caused by heart or pulmonary disease (e.g. COPD)\n* Aphasia, or dementia that interferer with understanding the protocol and\u002For physical examinations.\n* Patients diagnosed with dementia at hospital admission (a score ≤23\u002F30 on the Mini-Mental State Examination are not invited into the study)",{"count":164,"type":20},[58],"In a randomized controlled trial the effect of 12 weeks of cross-sectorial physical exercise combined with patient education and individual follow-up session is investigated in patients with minor stroke or non-disabling stroke.",[247,248,27],"Minor Stroke","Non-disabling Stroke",[250,251,252,253,254,255],"Minor stroke","Stroke prevention","Physical exercise","Patient education","Cardiorespiratory fitness","Non-disabling stroke","2025-04-29",{"date":258,"type":36},"2025-05-02",{"date":260,"type":36},"2022-06-01",{"date":262,"type":20},"2033-12",{"name":264,"class":43},"Herlev Hospital",2,{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":140,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":21,"phases":275,"briefSummary":278,"conditions":279,"keywords":280,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":294,"locationsCount":44},"100566297","phase-2-ticagrelor-based-de-escalation-of-dual-antiplatelet-therapy-in-ischemic-stroke-100566297","NCT06653348","Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke","De-Escalation of Dual Antiplatelet Therapy With Ticagrelor and Aspirin in Non-disabling Non-cardioembolic Ischemic Stroke or High Risk TIA Patients: A Randomized, Outcome Assessor Blind, Controlled Trial","DEDAPT-TICA","Inclusion Criteria:\n\n* signing inform consent,\n* recent ischemic stroke within 24 h,\n* diagnosed by brain CT or MRI mild stroke with NIHSS =\\\u003C8 and no evidence of large infarct in brain imaging\n* high risk TIA with ABCD \\>4,\n* no cardioembolic source such as low E\u002FF, MS, AF ,...\n* no specific etiology such as dissection, vasculitis, ...\n* no carotid stenosis \\> 50 % in side of involvement\n\nExclusion Criteria:\n\n* history of hypersensitivity to consumptive drug\n* any indication for anticoagulant therapy\n* acute phase treatment with intravenous thrombolysis or thrombectomy\n* any contraindication for consumptive drug\n* history of intracranial hemorrhage\n* history of GI bleeding during past 6 m\n* candidate for endarterectomy\n* history of coagulopathy\n* active hemorrhagic diathesis during randomization",{"count":164,"type":20},[276,277],"PHASE2","PHASE3","This is a randomized, controlled, outcome assessor blind, parallel group design pilot study on 100 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is to compare the efficacy of 90 mg ticagrelor BID plus aspirin for 1 month and 60 mg ticagrelor BID plus aspirin for 6 months in reduce of non-disabling non-cardioembolic ischemic stroke or high risk TIA recurrence during first 12 months.",[26,27],[281,282,283,284,285,286,287],"ischemic stroke","non-cardioembolic","non-disabling","TIA","Ticagrelor","de-escalation","dual antiplatelet therapy","2025-04-23",{"date":290,"type":36},"2025-04-27",{"date":292,"type":36},"2024-04-01",{"date":153,"type":20},{"name":295,"class":43},"Mazandaran University of Medical Sciences",{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":21,"phases":305,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":319},"100340314","empowerment-and-mobile-technology-in-the-control-of-cardiovascular-risk-factors-in-patients-with-ischemic-stroke-100340314","NCT03710902","Empowerment and Mobile Technology in the Control of Cardiovascular Risk Factors in Patients With Ischemic Stroke","CARDIOSTROKE","Inclusion Criteria:\n\n* Ischemic stroke or transient ischemic attack (ABCD2 score ≥3)\n* Age ≥40 years\n* Pre-existing or newly diagnosed hypertension\n* Informed consent from the patient or legal representative\n\nExclusion Criteria:\n\n* Known high-risk source of cardioembolism\n* Known indication for anticoagulation\n* Contraindication for anticoagulation\n* Pacemaker\n* Non-compliance to study interventions as judged by the investigator\n* Serious condition hampering the study conduct",{"count":304,"type":20},405,[58],"The CARDIOSTROKE is a randomized trial comparing mobile-device assisted control of hypertension together with screening of occult atrial fibrillation to standard care in patients with recent ischemic stroke or transient ischemic attack.",[26,27,308,89,309],"Atrial Fibrillation","Empowerment","2025-03-18",{"date":312,"type":36},"2025-03-20",{"date":314,"type":36},"2018-10-17",{"date":316,"type":20},"2028-09",{"name":318,"class":43},"Jukka Putaala",4,{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":327,"targetDuration":329,"studyType":143,"phases":4,"briefSummary":330,"conditions":331,"keywords":332,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":265},"100407238","stroke-card-registry-100407238","NCT04582825","Stroke-Card Registry","STROKE-CARD REGISTRY: Extension of Standard Care in Patients With Ischemic Stroke and Transient Ischemic Attack","Inclusion Criteria:\n\n* Patients with acute ischemic stroke or high-risk TIA (ABCD2-Score ≥ 4 points) treated at the Department of Neurology of each study center within 30 days after onset\n* Age ≥ 18 years\n* Written informed consent\n\nExclusion Criteria:\n\n* Patients living outside the catchment area of the participating centers\n* Patients under law enforcement or within mandatory military service\n* Age \\\u003C 18 years",{"count":328,"type":20},5000,"7 Years","Stroke is the second leading cause of death and one of the main contributors to disability. Patients who survive the acute phase of ischemic stroke and those with transient ischemic attack (TIA) are at high risk of subsequent vascular events. Importantly, recurrent strokes are associated with a higher social and economic impact, higher case fatality, and worse clinical outcome than first-ever strokes. The burden of post-stroke complications, residual deficits, and inadequate medical and psychosocial care all contribute to long-term disability and reduced quality of life in these patients. The Department of Neurology of the Medical University Innsbruck undertook the STROKE-CARD trial (NCT02156778) between 2014 and 2018 with follow-up until 2019 to evaluate the efficacy of the Post-Stroke disease-management program STROKE-CARD care. After implementation of STROKE-CARD care, the investigators aim to document the quality of post-stroke care and compare outcome parameters to historical cohorts and the change over time. Furthermore the investigators aim to gain a large data-resource for future research of biomarkers, disease mechanisms, prognosis and imaging mechanisms for R\\&D.",[26,27],[333,334,335,336,337],"Stroke secondary prevention","Stroke Risk factors","Biobank","Post-stroke care","Registry","2025-02-28",{"date":340,"type":36},"2025-03-05",{"date":342,"type":36},"2020-12-09",{"date":344,"type":20},"2027-07-31",{"name":346,"class":43},"VASCage GmbH",{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":16,"minAge":354,"maxAge":355,"enrollmentInfo":356,"targetDuration":4,"studyType":21,"phases":358,"briefSummary":359,"conditions":360,"keywords":361,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":4},"100576471","phase-4-statins-in-frail-older-patients-with-ischemic-stroke-or-transient-ischemic-attack---the-randomized-controlled-trial-100576471","NCT06785727","StAtins in Frail OldEr Patients with Ischemic Stroke or Transient Ischemic Attack - the Randomized Controlled Trial","SAFEST - RCT","Inclusion Criteria:\n\n* age = 70 years or older at the time of ischemic stroke or TIA;\n* inclusion within 6 weeks after diagnosis of ischemic stroke or TIA;\n* not using statin therapy at the time of the index event;\n* frailty as defined by a pre-event score of 4-7 and\u002For post-event score of 6-7 on the validated Clinical Frailty Scfale.\\[49\\]\n\nExclusion Criteria:\n\n* Patients with a stroke or TIA of non-atherosclerotic etiology.\n* Previous serious adverse drug reactions (defined as an adverse reaction that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, or is a birth defect40) to statins or other contraindications to statin use.\n* Very severe frailty or very limited life expectancy (\\\u003C 6 months) as defined by a score \\>= 8 points on the validated Clinical Frailty Scale.\n* Inability to communicate in Dutch.\n* Inability to respond to questions, either independently or with the assistance of a proxy (a proxy is allowed to assist by writing on behalf of the participant in cases of physical incapacity or by discussing questions with the participant, but the proxy cannot make decisions for the participant).\n* Inability or unwillingness to provide written informed consent, either independently or with the assistance of a proxy (a proxy is allowed to assist by writing on behalf of the participant in cases of physical incapacity or by discussing the consent form with the participant, but the proxy cannot make decisions or provide consent on behalf of the participant).\n* Extremely high-risk patients, i.e. patients who have had two or more cardiovascular events within a period of one year.","70 Years","120 Years",{"count":357,"type":20},612,[23],"Two Dutch guidelines (Stroke and Cardiovascular Risk Management) provide conflicting advice on optimal statin treatment in older patients. In the SAFEST - RCT, the investigators will assess the impact of starting versus not starting a statin in frail individuals aged 70 and above with a recent ischemic stroke or transient ischemic attack (TIA) on their health-related quality of life and Major Adverse Cardiovascular Events (MACE) free survival during a two-year follow-up period.",[26,27],[362,281,174,363],"statin","quality of life","2025-01-19",{"date":366,"type":36},"2025-01-21",{"date":368,"type":20},"2025-02-01",{"date":370,"type":20},"2029-07-01",{"name":372,"class":43},"Prof. dr. Nathalie van der Velde",{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":21,"phases":383,"briefSummary":384,"conditions":385,"keywords":387,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":44},"100516493","smartwatches-for-detection-of-atrial-fibrillation-afib-in-secondary-prevention-of-cryptogenic-stroke-100516493","NCT06005233","Smartwatches for Detection of Atrial Fibrillation (AFib) in Secondary Prevention of Cryptogenic Stroke","Smartwatches for Detection of Atrial Fibrillation (AFib) in Secondary Prevention of Cryptogenic Stroke - WATCH AFib A Prospective, Intraindividual-controlled, Multicenter Clinical Study","WATCH AFib","Inclusion Criteria:\n\n* Implanted Event Recorder with telemedicinal function (e.g., Biotronik BioMon 3m ProMRI HomeMon or similar)\n* Cryptogenic stroke (within the last six month) after full standard evaluation:\n\n  * Stroke detected by computed tomography (CT) or magnetic resonance imaging (MRI) that is not lacunar (lacunar is defined as a subcortical infarct in the distribution of the small, penetrating cerebral arteries whose largest dimension is ≤1.5 cm on CT or ≤2.0 cm on MRI diffusion images)\n  * Absence of extracranial or intracranial atherosclerosis causing ≥50 percent luminal stenosis of the artery supplying the area of ischemia\n  * No major-risk cardioembolic source of embolism (i.e., no permanent or paroxysmal atrial fibrillation, sustained atrial flutter, intracardiac thrombus, prosthetic cardiac valve, atrial myxoma or other cardiac tumors, high-grade mitral valve stenosis, recent (within four weeks) myocardial infarction, left ventricular ejection fraction \\\u003C30 percent, valvular vegetations, or infective endocarditis)\n  * No other specific cause of stroke identified (e.g., arteritis, dissection, migraine, vasospasm, drug abuse)\n  * No paroxysmal atrial fibrillation in 72h of in-hospital ECG-monitoring, including at least one Holter- ECG for 24 hours.\n* Cryptogenic TIA with definite cortical syndrome (aphasia, neglect or homonymous hemianopia) (within the last six month) after full standard evaluation (see above)\n* Age: ≥40 yrs.\n* At least one of the following risk factors:\n\n  * CHA2DS2VASc score ≥4\n  * Atrial runs\n  * Left atrial size \\> 45mm\n  * Left atrial appendage flow ≤ 0.2m\u002Fs\n* No contraindication for anticoagulant therapy after acute phase of stroke\n* Written informed consent by patient or authorized caregiver\n\nExclusion Criteria:\n\n* Patient is not able to perform 1-lead ECG recording with smartwatch\n* Patient possesses no smartphone (iOS version ≥10.0 or Android)\n* Implanted pacemaker or cardioverter defibrillator (ICD)\n* Pregnancy and breastfeeding period",{"count":382,"type":20},400,[58],"Scientific Background: In secondary prevention of ischemic stroke, detection of atrial fibrillation (AFib) and subsequent anticoagulation therapy reduce the risk of recurrent stroke by approximately 60%. Prolonged electrocardiogram (ECG) monitoring up to 6 months significantly increases detection of AFib in cryptogenic stroke. Wearables like smartwatches have recently been shown to adequately detect AFib in the general population. Thus, prolonged ECG monitoring after cryptogenic ischemic stroke or transient ischemic attack (TIA) using a smartwatch could lead to a reduction of recurrent stroke by prompting adequate anticoagulation therapy and may constitute a cost-effective, non-invasive, and broadly-available alternative to the current standard of care.\n\nHypothesis: The investigators hypothesize that AFib detection via smartwatch in patients with cryptogenic TIA or ischemic stroke is accurate compared to an implantable event recorder.\n\nMethods: The investigators introduce a prospective, intraindividual-controlled, multicentre clinical study in patients with cryptogenic ischemic stroke or TIA. In addition to an implanted event recorder as indicated by clinical standard, included patients receive a smartwatch for detection of AFib. ECG-data from smartwatches will be continuously monitored by two independent cardiologists. As soon as AFib is confirmed, a doctoral appointment is set to evaluate start of anticoagulation. The follow-up period will be six months. The study consists of four study visits: a baseline visit, two phone visits at one and three months, and an end of trial visit at six months.\n\nPrimary Objective: To compare smartwatch and event recorder based analysis for sensitivity and specificity of AFib detection per patient after six months",[386,27,308],"Ischemic Stroke, Cryptogenic",[388,389,115],"Smartwatch","Ischemic stroke","2024-12-09",{"date":392,"type":36},"2024-12-13",{"date":394,"type":36},"2024-10-15",{"date":396,"type":20},"2026-07",{"name":398,"class":43},"Technical University of Munich",{"id":400,"slug":401,"hasResults":11,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":405,"eligibilityCriteria":406,"healthyVolunteers":11,"sex":16,"minAge":407,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":21,"phases":410,"briefSummary":411,"conditions":412,"keywords":416,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":429},"100515753","phase-4-comparison-of-clopidogrel-based-antiplatelet-therapy-versus-warfarin-as-secondary-prevention-strategy-for-antiphospholipid-syndrome-related-stroke-100515753","NCT05995600","Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin As Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE","Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin As Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)","APS-STROKE","Inclusion Criteria:\n\n* Age 19 years or older\n* History of ischemic stroke (cerebral infarction, transient ischemic attack, or retinal arterial ischemic event)\n* Patients who meet the laboratory diagnostic criteria for antiphospholipid syndrome (APS)\n* Patients or guardians who agree to the study protocol and sign with informed consent\n\nExclusion Criteria:\n\n* Patients with high-risk antiphospholipid antibody profile (triple positivity; persistent high-titers exceeding 80 U\u002FmL of anti-cardiolipin or anti-β2 glycoprotein I antibodies)\n* Systemic lupus erythematous\n* Patients unable to discontinue previously taken anticoagulants or antiplatelet agents (e.g., atrial fibrillation, valvular heart disease, or a history of percutaneous coronary intervention)\n* Women who are pregnant, breastfeeding, or intending to become pregnant during the study period\n* Deemed unsuitable for participation in the study for more than four years, as per the investigators' discretion","19 Years",{"count":409,"type":20},200,[23],"Antiphospholipid syndrome (APS) has a close association with ischemic stroke; however, the optimal treatment strategy for APS-related stroke has yet to be established. The clinical guidelines suggest using warfarin for APS-related stroke, but these suggestions are largely based on retrospective studies from the 1990s and expert opinion, rather than high-quality clinical trials. Moreover, the evidence on the role of antiplatelet drugs other than aspirin (e.g., clopidogrel) in APS-related stroke is particularly limited. Considering the relatively young age of patients with APS and the high clinical burden of using warfarin, it is necessary to verify whether warfarin is essential. Thus, the investigators aim to compare clopidogrel-based antiplatelet therapy and warfarin as a secondary preventive medication for patients with APS-related stroke. APS-STROKE is an exploratory, multicenter, prospective, randomized, open, blinded-endpoint clinical trial. Adult patients with definite APS who have a history of ischemic stroke will be included. Patients with high-risk APS (triple positivity or persistently high titers of anti-cardiolipin or anti-β2-glycoprotein I antibodies), systemic lupus erythematous, or indications for continued antiplatelet or anticoagulant therapy will be excluded. Eligible patients will be 1:1 randomized to receive clopidogrel-based antiplatelet therapy or warfarin. Patients assigned to the clopidogrel-based antiplatelet therapy group will be permitted to use additional antiplatelet drugs other than clopidogrel at the investigator's discretion. The primary outcome is a composite of any death, major adverse cardiovascular events, systemic thromboembolic events, and major bleeding during a follow-up period of at least 4 years. This study would provide valuable information for determining the optimal secondary prevention strategy for APS-related stroke.",[413,26,27,414,88,415],"Antiphospholipid Syndrome","Cerebrovascular Disease","Major Bleed",[417,389,418,419],"Antiphospholipid syndrome","Secondary prevention","Thrombosis","2024-10-13",{"date":422,"type":36},"2024-10-16",{"date":424,"type":36},"2024-02-20",{"date":426,"type":20},"2029-03",{"name":428,"class":43},"Seoul National University Hospital",32,{"id":431,"slug":432,"hasResults":11,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":436,"eligibilityCriteria":437,"healthyVolunteers":140,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":438,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":440,"conditions":441,"keywords":444,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":44},"100488820","extracellular-vesicles-and-dysregulated-coagulation-in-the-prediction-of-stroke-100488820","NCT05645081","Extracellular Vesicles and Dysregulated Coagulation in the Prediction of Stroke","PREDICT-EV; the Association of Extracellular Vesicles and Dysregulated Coagulation in the Prediction of Stroke","PREDICT-EV","The inclusion criteria for phase 1 (initial patient recruitment) will be:\n\n1. Patients with or without diagnosis of TIA made by a physician working in stroke medicine, sufficiently so to start post-TIA care or so that no further investigation is thought necessary to confirm or refute the diagnosis.\n2. TIA confirmed patient has been prescribed antiplatelet drugs or anticoagulants.\n3. Patients must be aged \\> 18 years.\n4. Patients are taking an ordinary diet by mouth.\n\nThe inclusion criteria for phase 2 (patient representing with stroke) will be:\n\n1. Radiological evidence, on CT and\u002For MR imaging of the brain of cerebral infarction, with or without secondary haemorrhage.\n2. The underlying mechanism of cerebral infarction is embolic from a cardiac source (e.g. atrial fibrillation), atherothromboembolic (from aorta or other large vessels in the neck) or in-situ thrombosis. No further investigations are thought necessary to confirm or refute the diagnosis.\n3. No further investigations are thought necessary to confirm or refute the diagnosis.\n4. Patients must be aged \\>18 years.\n5. Patients must not be pregnant or breast feeding.\n6. Patients are taking an ordinary diet by mouth. Exclusion Criteria\n\nThe Exclusion criteria for phase 1 (initial patient recruitment) will be:\n\n1. Inability to give consent.\n2. Inability to feed by mouth.\n3. Short life expectancy.\n4. Pregnancy or breastfeeding.\n5. Symptoms are readily explained by medical problems not involving focal cerebral ischaemia.\n\nThe Exclusion criteria for phase 2 (patient representing with stroke) will be:\n\n1. Patients who have not previously given consent for follow up blood sampling.\n2. Patients who are unable to feed by mouth.\n3. Patients in whom life expectancy is short.\n4. Patient is pregnant or breast feeding.",{"count":439,"type":20},360,"Annually 100,000 strokes occur, placing stroke as the largest cause of disability in the UK. 90% of strokes are preventable, leading to national focus on programmes including \"The National Stroke Programme\" to act on preventing, treating, and improving post-stroke care. Importantly, over 25% of ischaemic stroke sufferers have previously had a Transient Ischaemic Attack (TIA), which presents the biggest concern for TIA patients. There are no measures which reliably identify TIA patients most likely to suffer a stroke. Novel biomarkers for predicting stroke are key to addressing this problem. The PREDICT-EV study aims to screen 300 TIA patients and follow them over 12-months. The investigators will determine if a novel biomarker we've identified to increase thrombotic risk (endothelial derived extracellular vesicles) and the resulting increased prothrombin time is associated with patients at highest risk of stroke.",[442,27,443],"Stroke, Ischemic","Coagulation Disorder",[445,27,446,447],"Stroke Risk","Extracellular Vesicles","Pro-Thrombotic Risk","2024-08-19",{"date":450,"type":36},"2024-08-20",{"date":452,"type":36},"2021-10-01",{"date":454,"type":20},"2027-09-01",{"name":456,"class":131},"Cwm Taf University Health Board (NHS)",{"id":458,"slug":459,"hasResults":11,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":4,"eligibilityCriteria":463,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":464,"targetDuration":465,"studyType":143,"phases":4,"briefSummary":466,"conditions":467,"keywords":468,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":44},"100555692","tia-scores-mortality-predictions-and-recurrent-tia-and-stroke-prediction-100555692","NCT06515392","TIA Scores' Mortality Predictions and Recurrent TIA and Stroke Prediction","The Role of TIA Scores and NIHSS Score in Predicting Early and Late Ischemic Stroke Risk in Patients Presenting With Transient Ischemic Attack to the Emergency Department","Inclusion Criteria:\n\nPatients presenting to the emergency department and diagnosed with TIA Patients diagnosed with ischemic stroke who did not receive thrombolytic therapy based on NIHSS score Patients aged 18 and above Patients who consented by signing the informed consent form\n\nExclusion Criteria:\n\nPatients diagnosed with hemorrhagic stroke Patients unwilling to participate in the study Patients with a history of trauma Patients unable to receive thrombolytic therapy for any reason (trauma, malignancy, etc.) Patients under the age of 18 Patients transferred from another hospital Patients who experienced cardiac arrest Patients who died for any reason other than ischemic stroke within 30 days Patients wishing to withdraw from the study at any time during the study period",{"count":222,"type":20},"30 Days","Our study adopts a prospective design. Our research aims to determine the significance of ABCD2, ABCD3-I, Canadian TIA Score, and NIHSS Score in predicting the likelihood of ischemic stroke within 30 days in patients presenting to the emergency department with transient ischemic attack (TIA)",[442,27],[174,281,469],"TIA scores","2024-07-17",{"date":472,"type":36},"2024-07-23",{"date":474,"type":36},"2024-06-01",{"date":476,"type":20},"2025-06-01",{"name":478,"class":43},"Saglik Bilimleri Universitesi",{"id":480,"slug":481,"hasResults":11,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":485,"eligibilityCriteria":486,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":487,"targetDuration":4,"studyType":21,"phases":489,"briefSummary":490,"conditions":491,"keywords":492,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":44},"100412187","phase-2-european-blood-pressure-intensive-control-after-stroke-100412187","NCT04647292","European Blood Pressure Intensive Control After Stroke","European Blood Pressure Intensive Control After Stroke - Pilot Trial","EPICS-Pilot","Inclusion Criteria:\n\n1. Age ≥40\n2. Ischaemic stroke1, high-risk TIA, proven by imaging (brain CT\u002FMRI)\n3. Living at home and independent (walking without the aid of another person, but may have some help for daily activities)\n4. SBP≥140mmHg at entry (average of 2 measures, seated, in the same arm, after resting alone in office for 10 minutes)\n5. Qualifying event between 30 days and 1 year of randomisation\n6. Glomerular filtration rate (eGFR) greater than or equal to 50ml\u002Fmin\u002Fm2 (within 3 months of randomisation)\n7. Medically-stable and capable of participating in a randomised trial, including home BP measures, in the opinion of the study physician\n8. Willing to provide informed consent (no surrogate consent will apply)\n\nExclusion Criteria:\n\n1. SBP \\\u003C110mmHg after 3 minutes of standing or other contra-indication to intensive SBP lowering in opinion of treating clinician (eg. Orthostatic symptoms, syncope or pre syncope, recurrent falls)\n2. Qualifying stroke due to intracerebral haemorrhage (ICH), cardio-embolism or other defined causes (eg. dissection, endocarditis, other specified)\n3. Severe stenosis or occlusion of large cranio-cervical artery (\\>70% stenosis\u002Focclusion of cervical carotid, vertebral, or Circle of Willis artery)\n4. Unlikely to comply with study procedures due to severe or fatal comorbid illness (eg. dementia, active malignancy, severe frailty) or other factor (eg. inability to travel)\n5. Pregnancy or breastfeeding",{"count":488,"type":20},142,[276],"Stroke is the third most common cause of death worldwide and the leading cause of disability. High blood pressure is an important risk factor for stroke. Lowering a person's blood pressure reduces the risk of future stroke or heart attack, and current guidelines recommend treatment to a target of \\\u003C130mmHg for secondary prevention.\n\nHome blood pressure measurement and telemonitoring are acceptable to patients, but there is uncertainty over the use of out of office blood pressure measurements in stroke patients in guidelines.\n\nThis is a study designed to establish the feasibility of a larger clinical trial, comparing home blood pressure monitoring, telemonitoring and medication titration with standard care. The study hypothesis is that home BP measurement and telemonitoring with medication titration may lead to improved BP control compared to standard of care clinical practice.",[26,27],[281,174,493,494,495,496,497,498,499,500],"blood pressure","hypertension","recurrence","prognosis","prevention","randomized control trial","myocardial infarction","vascular events","2024-07-09",{"date":503,"type":36},"2024-07-11",{"date":505,"type":36},"2024-05-02",{"date":507,"type":20},"2026-03",{"name":509,"class":43},"University College Dublin",{"id":511,"slug":512,"hasResults":11,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":516,"eligibilityCriteria":517,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":520,"conditions":521,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":4},"100552444","mobility-assessment-in-multi-morbidity-100552444","NCT06473168","Mobility Assessment in Multi-morbidity","Walking-related Mobility Assessment in Older People With Multimorbidity","Multi-mobility","Inclusion Criteria:\n\n* Adults ≥65 years old\n* Able and willing to provide informed consent\n* Able to read and write in English\n* To be mobile (including the use of walking aids)\n* Two or more of the following long terms conditions: Arthritis, Asthma, Atrial fibrillation, Bronchiectasis, Cancer, Chronic kidney disease, Chronic obstructive pulmonary disease, Coronary heart disease, Anxiety, Depression, Diabetes mellitus, Heart failure, Hypertension, Osteoporosis, Parkinson's disease, Peripheral vascular disease, Stroke or transient ischaemic attack\n\nExclusion Criteria:\n\n* Unable to give consent for the study\n* Severe mental health problems\n* Active malignancy (on chemotherapy\u002Fradiotherapy\u002Fplanned urgent surgery)",{"count":519,"type":20},55,"Multimorbidity (the presence of two or more coexisting long-term conditions) is a significant challenge facing the NHS, especially given UK's ageing population and the association with high levels of illness burden and healthcare costs. Over 50% of adults \\>65 years have multiple long-term conditions (MLTCs).\n\nOur group has validated a broad range of algorithms applied to single wearable sensors that have the potential to capture walking-related mobility outcomes (such as walking cadence and walking speed) accurately and reliably during activities of daily living across five single long-term conditions. These algorithms, however, cannot be readily applied to people with MLTCs because the effect of multimorbidity on mobility is amplified compared to single long-term conditions secondary to a greater number of complications and sequelae. Accordingly, the aim of this study is to validate algorithms that would allow robust estimation of walking-related mobility outcomes during daily life activities in MLTCs.\n\nTo meet our objectives, the investigators will perform: i) laboratory-based technical validation of existing and newly developed algorithms for walking-related mobility outcome detection; ii) unsupervised real-life validation of selected algorithms; and iii) examination of how well the validated walking-related mobility outcomes reflect global and disease specific characteristics in older adults with multimorbidity. The investigators will adopt an integrated patient-centric approach where patients with MLTCs will be engaged early in the project to provide input of their perception and concerns regarding mobility limitation in daily life activities.\n\nThe investigators aim to recruit 55 older adults (\\>65 years), men and women, with multiple long-term conditions with the following inclusion criteria: having two or more of the following conditions including osteoarthritis, rheumatoid arthritis, osteoporosis, type 2 diabetes, depression and\u002For anxiety, hypertension, coronary heart disease, heart failure, atrial fibrillation, chronic obstructive pulmonary disease, asthma, bronchiectasis, chronic kidney disease, cancer, or stroke within the last 5 years.",[522,523,308,524,525,526,527,528,529,530,531,532,89,533,534,535,61,27],"Arthritis","Asthma","Bronchiectasis","Cancer","Chronic Kidney Diseases","Chronic Obstructive Pulmonary Disease","Coronary Heart Disease","Anxiety","Depression","Diabetes Mellitus","Heart Failure","Osteoporosis","Parkinson Disease","Peripheral Vascular Disease","2024-06-18",{"date":538,"type":36},"2024-06-25",{"date":540,"type":20},"2024-12-01",{"date":542,"type":20},"2025-12-31",{"name":544,"class":43},"Northumbria University",{"id":546,"slug":547,"hasResults":11,"nctId":548,"briefTitle":549,"officialTitle":549,"acronym":550,"eligibilityCriteria":551,"healthyVolunteers":140,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":554,"conditions":555,"keywords":565,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":44},"100550145","cerebrovascular-disease-quality-of-life-code-qol-100550145","NCT06443268","Cerebrovascular Disease: Quality of Life (CODE: QoL)","CODE:QoL","Control group:\n\nInclusion criteria:\n\n* over 18 years old\n* No previous stroke OR previous stroke \\>3 years ago\n* No significant disability (maximum mRS 1)\n* ambulatory patients at the University Hospital of Zurich (USZ), Dept. of Neurology\n* Patients' AND caregiver's ability to give informed consent\n* Patients' AND close relative's \u002F caregiver's willingness to participate\n\nExclusion criteria:\n\n• Medication with steroid hormones (prednisone, prednisolone, dexamethasone, methylprednisolone, hydrocortisone etc.) within last 3 months\n\nMain Group:\n\nInclusion criteria:\n\n* over 18 years old\n* Patients diagnosed with either transient ischemic attack, ischemic stroke or intracerebral hemorrhage and their caregivers\n* Caregiver of a patient as described above, age over 18 years\n* Hospitalized or ambulatory patients at the University Hospital of Zurich (USZ) included within 28 days from event.\n* Patients' AND caregiver's ability to give informed consent\n* Patients' AND caregiver's willingness to participate\n\nExclusion criteria:\n\n• Medication with steroid hormones (prednisone, prednisolone, dexamethasone, methylprednisolone, hydrocortisone etc.) within last 3 months",{"count":553,"type":20},680,"The goal of this observational study is to learn about quality of life, stress and caregiver burden in patients with stroke and their caregivers.\n\nThe main question is:\n\n• to discover the factors associated with quality of life and stress in patient-caregiver dyads.\n\nParticipants will be asked to fill out questionnaires and agree to provide a hair sample (in order to measure stress hormones in hair) and consent to use of their routine clinical and laboratory data.\n\nResearchers will compare a group of participants without stroke to establish a comparable baseline.",[556,557,558,559,560,561,562,27,563,564],"Quality of Life","Stroke, Acute","Sexual Behavior","Stress","Cortisol Excess","Incontinence, Urinary","Caregiver Burden","Intracerebral Hemorrhage","Cerebrovascular Disorders",[566],"Stroke, QoL, HRQoL, Patient-Caregiver dyads, Stress, Burden","2024-05-29",{"date":569,"type":36},"2024-06-05",{"date":571,"type":36},"2023-05-27",{"date":573,"type":20},"2028-06-30",{"name":575,"class":43},"University of Zurich",{"id":577,"slug":578,"hasResults":11,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":4,"eligibilityCriteria":582,"healthyVolunteers":140,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":583,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":585,"conditions":586,"keywords":588,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":605,"locationsCount":265},"100371623","microstructure-imaging-in-stroke-patients-100371623","NCT04118790","Microstructure Imaging in Stroke Patients","New Clinical Magnetic Resonance Technologies for Capturing Brain Microstructure Alterations in Patients With Minor Stroke or Transient Ischemic Attack","Patient Inclusion Criteria:\n\n* Stroke or TIA (ABCD2\\>4 and\u002For acute Diffusion-Weighted Image (DWI) lesion).\n* Modified Rankin Scale \\\u003C=2.\n* As perceived by the investigator, have the ability to comply with all requirements of the study protocol.\n* Have the ability to understand and sign the Informed Consents Form.\n* Multidimensional Fatigue Inventory score \\>= 12 on general fatigue.\n\nPatient Exclusion Criteria:\n\n* The DRCMR´s general exclusion criteria for MRI research.\n* Pregnancy or lactation; human chorionic gonadotropin (hCG) urine test is offered for women \\\u003C 55 years.\n* Major medical illness (for instance: anemia, diabetes mellitus, thyroid disorders, cardiovascular disease, electrolyte imbalance, etc.)\n* Treated with ritalin or modafinil.\n* Known uncontrolled severe malignancy.\n* Known drug or alcohol addiction.\n* Tiredness due to pharmaceutical side effects, as identified by the Investigator.\n* Max body weight of 130 kg.\n* Persons who do not wish to be informed about abnormal findings as part of the investigations.\n\nHealthy Controls Exclusion Criteria:\n\n* The DRCMR´s general exclusion criteria for MRI research.\n* Pregnancy or lactation; urin hCG test is offered for women \\\u003C 55 years.\n* Major medical illness (for instance: anemia, diabetes mellitus, thyroid disorders, cardiovascular disease, electrolyte imbalance, etc.)\n* Anamnestic infection (cystitis, influenza, pneumonia, etc) the last 3 weeks.\n* Known malignancy.\n* Known drug or alcohol addiction.\n* Tiredness due to pharmaceutical side effects.\n* Max body weight of 130 kg.\n* Persons who do not wish to be informed about abnormal findings as part of the investigations.\n\nHealthy Controls Inclusion Criteria:\n\n* Healthy\n* Age- and sex-matched to patient groups.\n* As perceived by the investigator, have the ability to comply with all requirements of the study protocol.\n* Have the ability to understand and sign the Informed Consents Form.",{"count":584,"type":20},90,"The purpose of this study is to establish a methodological framework based on existing advanced neuroimaging technologies as a new clinical neuroimaging tool for assessment of possible affected brain connections in stroke and TIA patients. Thus, providing new insights into microstructural changes that may underline why those patients experience deficits like fatigue.",[587,557,27],"Fatigue",[587,589,284,590,591,592,593,594,595,596,597],"minor stroke","Diffusion","MRI","Quantitative","Sequence","Microstructure","Axon","Myelin","Degeneration","2022-05-25",{"date":600,"type":36},"2022-05-26",{"date":602,"type":36},"2019-12-23",{"date":604,"type":20},"2029-03-01",{"name":606,"class":43},"Danish Research Centre for Magnetic Resonance"]